Lièvre A - Search Results

1

[Predictive factors in the response of antiplatelet anti EFGR in gastro-intestinal tumor].

Puig PL, Lièvre A. Puig PL, et al. Among authors: lievre a. Therapie. 2007 Mar-Apr;62(2):95-8. doi: 10.2515/therapie:2007026. Epub 2007 Jun 21. Therapie. 2007. PMID: 17582308 French. No abstract available.

2

[Predictive factors of response to anti-EGFR treatments in colorectal cancer].

Lièvre A, Laurent-Puig P. Lièvre A, et al. Bull Cancer. 2008 Jan;95(1):133-40. doi: 10.1684/bdc.2008.0551. Bull Cancer. 2008. PMID: 18230579 Review. French.

3

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P. Lièvre A, et al. Cancer Res. 2006 Apr 15;66(8):3992-5. doi: 10.1158/0008-5472.CAN-06-0191. Cancer Res. 2006. PMID: 16618717

4

Mutations and response to epidermal growth factor receptor inhibitors.

Laurent-Puig P, Lievre A, Blons H. Laurent-Puig P, et al. Among authors: lievre a. Clin Cancer Res. 2009 Feb 15;15(4):1133-9. doi: 10.1158/1078-0432.CCR-08-0905. Clin Cancer Res. 2009. PMID: 19228718 Review.

5

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F. Laurent-Puig P, et al. Among authors: lievre a. J Clin Oncol. 2009 Dec 10;27(35):5924-30. doi: 10.1200/JCO.2008.21.6796. Epub 2009 Nov 2. J Clin Oncol. 2009. PMID: 19884556

6

Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.

Perkins G, Lièvre A, Ramacci C, Méatchi T, de Reynies A, Emile JF, Boige V, Tomasic G, Bachet JB, Bibeau F, Bouché O, Penault-Llorca F, Merlin JL, Laurent-Puig P. Perkins G, et al. Among authors: lievre a. Int J Cancer. 2010 Sep 1;127(6):1321-31. doi: 10.1002/ijc.25152. Int J Cancer. 2010. PMID: 20049837

7

Oncogenic mutations as predictive factors in colorectal cancer.

Lièvre A, Blons H, Laurent-Puig P. Lièvre A, et al. Oncogene. 2010 May 27;29(21):3033-43. doi: 10.1038/onc.2010.89. Epub 2010 Apr 12. Oncogene. 2010. PMID: 20383189 Review.

8

[Biology applied to cancer treatments: the example of colorectal cancer].

Lièvre A, Laurent-Puig P. Lièvre A, et al. Rev Prat. 2010 Oct 20;60(8):1100-2. Rev Prat. 2010. PMID: 21197742 French. No abstract available.

9

Genetics: Predictive value of KRAS mutations in chemoresistant CRC.

Lièvre A, Laurent-Puig P. Lièvre A, et al. Nat Rev Clin Oncol. 2009 Jun;6(6):306-7. doi: 10.1038/nrclinonc.2009.69. Nat Rev Clin Oncol. 2009. PMID: 19483733

10

Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma.

Lièvre A, Blons H, Houllier AM, Laccourreye O, Brasnu D, Beaune P, Laurent-Puig P. Lièvre A, et al. Br J Cancer. 2006 Mar 13;94(5):692-7. doi: 10.1038/sj.bjc.6602993. Br J Cancer. 2006. PMID: 16495928 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

174 results

Search Page

Filters